Olema Pharmaceuticals (OLMA) Other financing activities (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Other financing activities data on file, last reported at $8.4 million in Q1 2026.

• On a quarterly basis, Other financing activities rose 3472.03% year-over-year to $8.4 million in Q1 2026; TTM through Mar 2026 was $16.6 million, a 93.17% decrease from a year earlier, with the FY2025 full-year figure at $8.4 million, down 96.55% from the prior year.
• Other financing activities for Q1 2026 stood at $8.4 million, up from $7.9 million in the prior quarter.
• Over the last five years, Other financing activities for OLMA reached as high as $242.4 million in Q4 2024 and fell as low as $7000.0 in Q2 2022.
• Historically, Other financing activities has averaged $24.4 million across 5 years, with a median of $235000.0 in 2025.
• Across the five-year window, Other financing activities jumped 18928.57% in 2023 and plunged 96.75% in 2025, its largest moves.
• Year by year, Other financing activities stood at $106000.0 in 2022, then soared by 120008.49% to $127.3 million in 2023, then surged by 90.41% to $242.4 million in 2024, then plunged by 96.75% to $7.9 million in 2025, then advanced by 6.98% to $8.4 million in 2026.
• Per Business Quant data, the three most recent Other financing activities figures were $8.4 million in Q1 2026, $7.9 million in Q4 2025, and $41000.0 in Q3 2025.